Radyoterapinin Pulmoner Komlikasyonları
Özet
Radyoterapi (RT), torasik ve göğüs dışı tümörlerin tedavisinde yaygın olarak kullanılan kritik bir yöntemdir. Ancak iyonize radyasyon, kanserli hücreleri yok ederken sağlıklı akciğer dokularına da zarar vererek Radyasyona Bağlı Akciğer Hasarına (RILI) yol açabilmektedir. İlk kez 1922 yılında tanımlanan bu durum, temelde iki aşamada incelenir: Tedaviden sonraki ilk altı ayda ortaya çıkan akut "radyasyon pnömonitisi" (RP) ve genellikle bir yıldan sonra gelişen ilerleyici "radyasyon pulmoner fibrozisi" (RPF). Hasarın gelişmesinde uygulanan radyasyon dozu, maruz kalan akciğer hacmi, ileri yaş, sigara öyküsü ve eş zamanlı kemoterapi kullanımı gibi faktörler belirleyici rol oynar. Klinik tanıda dispne, kuru öksürük ve ateş gibi semptomların yanı sıra bilgisayarlı toraks tomografisindeki (BT) buzlu cam görünümleri esastır. Tedavi yaklaşımında, asemptomatik hastalar için sadece klinik gözlem yeterliyken, orta ve ağır semptom gösteren olgularda temel tedavi seçeneği kortikosteroidlerdir. Ayrıca, amifostin veya pentoksifilin gibi ajanların da komplikasyonları azaltmada faydalı olabileceği gösterilmiştir. Yeni nesil üç boyutlu radyoterapi teknikleri sayesinde günümüzde ciddi pulmoner yan etkilerin görülme sıklığı giderek azalmaktadır.
Radiotherapy (RT) is a critical and widely utilized treatment modality for both lung and extra-thoracic malignancies. However, while destroying tumor cells, ionizing radiation can damage healthy lung tissue, leading to Radiation-Induced Lung Injury (RILI). First described in 1922, this condition is classified into two main phases: acute "radiation pneumonitis" (RP), which typically occurs within the first six months, and progressive "radiation pulmonary fibrosis" (RPF), which develops after one year. Key risk factors contributing to this toxicity include total radiation dose, irradiated lung volume, advanced age, smoking history, and concurrent chemotherapy. Clinical diagnosis is primarily based on symptoms such as dyspnea, dry cough, and low-grade fever, complemented by characteristic ground-glass opacities on chest computed tomography (CT). Regarding management, clinical observation is sufficient for asymptomatic cases, whereas oral corticosteroids represent the cornerstone of treatment for moderate to severe symptoms. Additionally, cytoprotective or immunomodulatory agents like amifostine and pentoxifylline may help mitigate complications. Fortunately, advanced three-dimensional radiation techniques have significantly reduced the incidence of severe pulmonary complications today.
Referanslar
Gabriele N, Burnet NG, Shankar S, et al. Radiotherapy toxicity (Primer). Nature Reviews: Disease Primers. 2019;5(1).
Käsmann L, Dietrich A, Staab-Weijnitz CA, et al. Radiation-induced lung toxicity–cellular and molecular mechanisms of pathogenesis, management, and literature review. Radiation Oncology. 2020;15(1):1-16.
Sekine I, Sumi M, Ito Y, et al. Retrospective analysis of steroid therapy for radiation-induced lung injury in lung cancer patients. Radiotherapy and oncology. 2006;80(1):93-97.
GROOVER TA. Observation on the use of the copperfilter in the roentgen treatment of deep-seated malignancies. Southern Med J. 1922;15:440-444.
Evans WA, Leucutia T. Intrathoracic changes induced by heavy radiation. Am J Roentgenol. 1925;13:203-220.
Hanania AN, Mainwaring W, Ghebre YT, et al. Radiation-induced lung injury: assessment and management. Chest. 2019;156(1):150-162.
Huang Y, Zhang W, Yu F, et al. The cellular and molecular mechanism of radiation-induced lung injury. Medical science monitor: international medical journal of experimental and clinical research. 2017;23:3446.
Fleckenstein K, Zgonjanin L, Chen L, et al. Temporal onset of hypoxia and oxidative stress after pulmonary irradiation. International Journal of Radiation Oncology* Biology* Physics. 2007;68(1):196-204.
Rübe CE, Uthe D, Schmid KW, et al. Dose-dependent induction of transforming growth factor β (TGF-β) in the lung tissue of fibrosis-prone mice after thoracic irradiation. International Journal of Radiation Oncology* Biology* Physics. 2000;47(4):1033-1042.
Rubin P, Johnston CJ, Williams JP, et al. A perpetual cascade of cytokines postirradiation leads to pulmonary fibrosis. International Journal of Radiation Oncology* Biology* Physics. 1995;33(1):99-109.
Arroyo-Hernández M, Maldonado F, Lozano-Ruiz F, et al. Radiation-induced lung injury: current evidence. BMC Pulmonary Medicine. 2021;21(1):1-12.
Rahi MS, Parekh J, Pednekar P, et al. Radiation-Induced Lung Injury—Current Perspectives and Management. Clinics and Practice. 2021;11(3):410-429.
Harder EM, Park HS, Chen ZJ, et al. Pulmonary dose-volume predictors of radiation pneumonitis following stereotactic body radiation therapy. Practical radiation oncology. 2016;6(6):e353-e359.
Chargari C, Riet F, Mazevet M, et al. Complications of thoracic radiotherapy. La Presse Médicale. 2013;42(9):e342-e351.
Sha S, Dong J, Wang M, et al. Risk factors for radiation-induced lung injury in patients with advanced non-small cell lung cancer: implication for treatment strategies. World Journal of Surgical Oncology. 2021;19(1):1-6.
Vogelius IR, Bentzen SM. A literature-based meta-analysis of clinical risk factors for development of radiation induced pneumonitis. Acta oncologica. 2012;51(8):975-983.
Rashdan S, Minna JD, Gerber DE. Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy. The Lancet Respiratory Medicine. 2018;6(6):472-478.
Delaunay M, Cadranel J, Lusque A, et al. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. European Respiratory Journal. 2017;50(2).
Ball DL, Fisher RJ, Burmeister BH, et al. The complex relationship between lung tumor volume and survival in patients with non-small cell lung cancer treated by definitive radiotherapy: a prospective, observational prognostic factor study of the Trans-Tasman Radiation Oncology Group (TROG 99.05). Radiotherapy and Oncology. 2013;106(3):305-311.
Yamagishi T, Kodaka N, Kurose Y, et al. Analysis of predictive parameters for the development of radiation-induced pneumonitis. Annals of thoracic medicine. 2017;12(4):252.
Wang Z, Huo B, Wu Q, et al. The role of procalcitonin in differential diagnosis between acute radiation pneumonitis and bacterial pneumonia in lung cancer patients receiving thoracic radiotherapy. Scientific reports. 2020;10(1):1-6.
Choi YW, Munden RF, Erasmus JJ, et al. Effects of radiation therapy on the lung: radiologic appearances and differential diagnosis. Radiographics. 2004;24(4):985-997.
Giordano FM, Ippolito E, Quattrocchi CC, et al. Radiation-Induced Pneumonitis in the Era of the COVID-19 Pandemic: Artificial Intelligence for Differential Diagnosis. Cancers. 2021;13(8):1960.
Mesurolle B, Qanadli SD, Merad M, et al. Unusual radiologic findings in the thorax after radiation therapy. Radiographics. 2000;20(1):67-81.
Park KJ, Chung JY, Chun MS, et al. Radiation-induced lung disease and the impact of radiation methods on imaging features. Radiographics. 2000;20(1):83-98.
Guerra JLL, Gomez D, Zhuang Y, et al. Change in diffusing capacity after radiation as an objective measure for grading radiation pneumonitis in patients treated for non-small-cell lung cancer. International Journal of Radiation Oncology* Biology* Physics. 2012;83(5):1573-1579.
Nakayama Y, Makino S, Fukuda Y, et al. Activation of lavage lymphocytes in lung injuries caused by radiotherapy for lung cancer. International journal of radiation oncology, biology, physics. 1996;34(2):459-467.
McCarty MJ, Lillis P, Vukelja SJ. Azathioprine as a steroid-sparing agent in radiation pneumonitis. Chest. 1996;109(5):1397-1400.
Muraoka T, Bandoh S, Fujita J, et al. Corticosteroid refractory radiation pneumonitis that remarkably responded to cyclosporin A. Internal medicine. 2002;41(9):730-733.
Qin W, Liu B, Yi M, et al. Antifibrotic agent pirfenidone protects against development of radiation-induced pulmonary fibrosis in a murine model. Radiation research. 2018;190(4):396-403.
De Ruysscher D, Granton PV, Lieuwes NG, et al. Nintedanib reduces radiation-induced microscopic lung fibrosis but this cannot be monitored by CT imaging: a preclinical study with a high precision image-guided irradiator. Radiotherapy and Oncology. 2017;124(3):482-487.
Epler GR, Kelly EM. Systematic review of postradiotherapy bronchiolitis obliterans organizing pneumonia in women with breast cancer. The oncologist. 2014;19(12):1216-1226.
Epler GR, Kelly EM. Post-Breast Cancer Radiotherapy Bronchiolitis Obliterans Organizing Pneumonia. Respiratory care. 2020;65(5):686-692.
Lee SJ, Yi CO, Heo RW, et al. Clarithromycin Attenuates Radiation-Induced Lung Injury in Mice. PloS one. 2015;10(6):e0131671.
Giuranno L, Ient J, De Ruysscher D, et al. Radiation-Induced Lung Injury (RILI). Frontiers in oncology. 2019;9:877.
Ozturk B, Egehan I, Atavci S, et al. Pentoxifylline in prevention of radiation-induced lung toxicity in patients with breast and lung cancer: a double-blind randomized trial. Int J Radiat Oncol Biol Phys. 2004;58(1):213-219.
Kharofa J, Cohen EP, Tomic R, et al. Decreased risk of radiation pneumonitis with incidental concurrent use of angiotensin-converting enzyme inhibitors and thoracic radiation therapy. Int J Radiat Oncol Biol Phys. 2012;84(1):238-243.
Simone NL, Soule BP, Gerber L, et al. Oral pirfenidone in patients with chronic fibrosis resulting from radiotherapy: a pilot study. Radiation oncology (London, England). 2007;2:19.
